Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
1.700
+0.020 (1.19%)
At close: Aug 15, 2025, 4:00 PM
1.670
-0.030 (-1.76%)
After-hours: Aug 15, 2025, 7:57 PM EDT
Milestone Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
33
Market Cap
166.39M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.00M | -4.00M | -80.00% |
| Dec 31, 2022 | 5.00M | -10.00M | -66.67% |
| Dec 31, 2021 | 15.00M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
MIST News
- 3 days ago - Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update - GlobeNewsWire
- 4 weeks ago - Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution - Seeking Alpha
- 5 weeks ago - Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge - Benzinga
- 5 weeks ago - Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants - GlobeNewsWire
- 5 weeks ago - Milestone Pharmaceuticals Announces Proposed Public Offering - GlobeNewsWire
- 5 weeks ago - Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray - GlobeNewsWire
- 5 weeks ago - Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst - Seeking Alpha
- 2 months ago - Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting - GlobeNewsWire